Rare Disease Therapeutics

Think Bioscience Secures $55M Series A to Drug “Undruggable” Targets

Boulder, Colorado, January 20, 2026 — Think Bioscience, a privately held biotechnology company focused on unlocking historically “undruggable” drug...

By cGxPwire Editor
January 21, 2026

Bio-Pharma Pharma

Zydus Therapeutics Reports Positive Topline Results from EPICS-III Trial of Saroglitazar Magnesium in Primary Biliary Cholangitis

Zydus Therapeutics, Inc., a U.S.-based innovation arm of Zydus Lifesciences Ltd., today announced positive topline data from its pivotal...

By cGxPwire Editor
August 29, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

Rare Disease Therapeutics

Think Bioscience Secures $55M Series A to Drug “Undruggable” Targets

Zydus Therapeutics Reports Positive Topline Results from EPICS-III Trial of Saroglitazar Magnesium in Primary Biliary Cholangitis